Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederfiercebiotech.com
FierceBiotech
Get the latest updates from FierceBiotech directly as they happen.
Follow now 332 followers
Latest posts
Last updated about 2 hours ago
Spatial Biomarker Panels for Clinical Trials
about 2 hours ago
This webinar covers how recent advances in multiplex immunofluorescence technology are enabling...
‘Like talking to a brick wall’: Senate hearing takes aim at FDA’s rare disease review process
about 6 hours ago
A panel of physicians, biotech leaders and patient advocates took aim at...
As CAR-T cell therapy gains ground on solid tumors, regulatory red tape hinders progress
about 7 hours ago
A new highly sensitive cell therapy was able to wipe out three...
Analysts see potential in MDMA drug after AtaiBeckley reports improvements in anxiety trial
about 8 hours ago
The trial was the first to assess R-MDMA in patients with social...
Sarepta CEO Doug Ingram to retire after a decade of Duchenne breakthroughs and controversies
about 11 hours ago
Sarepta Therapeutics CEO Doug Ingram announced Wednesday that he will retire by...
Protagonist plans to pocket $400M from Takeda rather than split US rusfertide profits
about 12 hours ago
While the FDA mulls whether to approve Protagonist Therapeutics’ hematology asset, the...
Bristol Myers’ $800M ADC hits primary survival endpoints in phase 3 breast cancer trial
about 13 hours ago
A Chinese phase 3 trial of Bristol Myers Squibb’s antibody-drug conjugate has...
Quantum Surgical snaps up J&J's NeuWave Medical for its microwave ablation technology
about 13 hours ago
Quantum Surgical is looking to become the “leader in the interventional radiology...
Boehringer pens $500M pact with British biotech for oral approach to autoimmune diseases
about 15 hours ago
Boehringer is banking on the program offering a new oral and precision...
Accent halts solid tumor trial over adverse events, pivots to other lead cancer program
about 17 hours ago
Accent Therapeutics has halted work on a solid tumor drug due to...
Asahi Kasei scoops up Germany's Aicuris for $920M in R&D portfolio boost
about 20 hours ago
Japanese conglomerate Asahi Kasei is acquiring Aicuris in a $920 million deal...
Charles River sells manufacturing and discovery businesses to fulfill promised pivot
1 day ago
After promising to sell off 7% of its business back in November...